S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet

IO Biotech (IOBT) Competitors

$1.76
+0.16 (+10.00%)
(As of 03/1/2024 ET)

IOBT vs. ANVS, CUE, CARM, CMRX, VACC, BRNS, BTAI, SYRE, VAXX, and RVPH

Should you be buying IO Biotech stock or one of its competitors? The main competitors of IO Biotech include Annovis Bio (ANVS), Cue Biopharma (CUE), Carisma Therapeutics (CARM), Chimerix (CMRX), Vaccitech (VACC), Barinthus Biotherapeutics (BRNS), BioXcel Therapeutics (BTAI), Spyre Therapeutics (SYRE), Vaxxinity (VAXX), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical preparations" industry.

IO Biotech vs.

IO Biotech (NASDAQ:IOBT) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, community ranking, profitability, valuation, institutional ownership and risk.

In the previous week, Annovis Bio had 6 more articles in the media than IO Biotech. MarketBeat recorded 8 mentions for Annovis Bio and 2 mentions for IO Biotech. IO Biotech's average media sentiment score of 0.62 beat Annovis Bio's score of -0.14 indicating that IO Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IO Biotech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Annovis Bio
0 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

IO Biotech has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500.

14.2% of Annovis Bio shares are held by institutional investors. 3.5% of IO Biotech shares are held by insiders. Comparatively, 38.3% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

IO Biotech currently has a consensus price target of $8.33, suggesting a potential upside of 373.48%. Annovis Bio has a consensus price target of $27.75, suggesting a potential upside of 212.85%. Given IO Biotech's stronger consensus rating and higher probable upside, research analysts plainly believe IO Biotech is more favorable than Annovis Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IO Biotech
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Annovis Bio
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Annovis Bio received 2 more outperform votes than IO Biotech when rated by MarketBeat users. Likewise, 93.33% of users gave Annovis Bio an outperform vote while only 85.71% of users gave IO Biotech an outperform vote.

CompanyUnderperformOutperform
IO BiotechOutperform Votes
12
85.71%
Underperform Votes
2
14.29%
Annovis BioOutperform Votes
14
93.33%
Underperform Votes
1
6.67%

Annovis Bio is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IO BiotechN/AN/A-$71.46M-$2.45-0.72
Annovis BioN/AN/A-$25.33M-$4.27-2.08

IO Biotech's return on equity of -60.81% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
IO BiotechN/A -60.81% -55.18%
Annovis Bio N/A -195.55%-156.80%

Summary

IO Biotech and Annovis Bio tied by winning 7 of the 14 factors compared between the two stocks.


Get IO Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IOBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IOBT vs. The Competition

MetricIO BiotechPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$115.95M$6.75B$5.11B$7.64B
Dividend YieldN/A2.83%2.82%3.87%
P/E Ratio-0.727.68167.3713.65
Price / SalesN/A235.673,058.6877.08
Price / CashN/A19.33100.6555.48
Price / Book0.374.654.534.53
Net Income-$71.46M$155.01M$115.01M$211.55M
7 Day Performance16.56%7.79%5.72%3.36%
1 Month Performance-3.56%15.91%12.82%6.70%
1 Year Performance-32.82%8.07%12.94%7.44%

IO Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANVS
Annovis Bio
1.3302 of 5 stars
$9.78
+10.3%
$34.25
+250.2%
-45.3%$103.47MN/A-2.295Analyst Downgrade
CUE
Cue Biopharma
3.5509 of 5 stars
$2.36
+11.3%
$8.67
+267.2%
-29.7%$106.48M$1.25M-1.9851Short Interest ↑
News Coverage
High Trading Volume
CARM
Carisma Therapeutics
2.1348 of 5 stars
$2.54
+0.4%
$10.00
+293.7%
N/A$102.51M$40M-0.68N/AGap Down
CMRX
Chimerix
4.5315 of 5 stars
$1.21
+1.7%
$8.00
+563.9%
-30.8%$107.11M$33.82M-1.2689Analyst Report
Analyst Revision
News Coverage
VACC
Vaccitech
0.6247 of 5 stars
$2.81
+1.8%
$9.31
+232.0%
-6.1%$108.12M$13.42M-1.9633News Coverage
Gap Up
BRNS
Barinthus Biotherapeutics
2.8636 of 5 stars
$2.81
+1.8%
$15.00
+434.8%
N/A$108.16M$44.70M-1.39107Short Interest ↓
News Coverage
Positive News
BTAI
BioXcel Therapeutics
4.1362 of 5 stars
$3.32
+7.1%
$21.13
+536.3%
-89.3%$100.87M$1.24M-0.45183Short Interest ↑
SYRE
Spyre Therapeutics
1.4814 of 5 stars
$24.91
+3.8%
$33.50
+34.5%
N/A$100.86M$1.05M-0.3369Analyst Upgrade
Short Interest ↑
Analyst Revision
News Coverage
Gap Up
High Trading Volume
VAXX
Vaxxinity
2.3867 of 5 stars
$0.77
+8.4%
$7.00
+803.5%
-65.8%$98.21M$70,000.00-1.4987Positive News
Gap Up
RVPH
Reviva Pharmaceuticals
2.4603 of 5 stars
$4.01
-7.8%
$16.75
+317.7%
-19.0%$111.96MN/A-2.4010News Coverage

Related Companies and Tools

This page (NASDAQ:IOBT) was last updated on 3/3/2024 by MarketBeat.com Staff